The US Supreme Court has blocked lower-court restrictions on the abortion pill mifepristone, preserving mail-order and pharmacy access without in-person doctor visits while a lawsuit proceeds. This is a significant development following the court's 2022 overturning of Roe v. Wade, impacting abortion access in over a dozen states that have effectively banned the procedure. For exam aspirants, this highlights judicial review, federalism, and the intersection of healthcare regulation and social policy in a major global polity.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Drug in Question: Mifepristone
- ›FDA Approval Year: 2000
- ›Target this Data: Medication abortions accounted for nearly two-thirds of all US abortions in 2023.
- ›Target this Nodal Body: The US Food and Drug Administration (FDA) which approved mifepristone in 2000.
- ›Target this Legal Point: The Comstock Act, a 19th-century law banning mailing of abortion-related materials, cited in Justice Thomas's dissent.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.